查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2135422

顆粒細胞增生因子市場：全球市場預測，2026-2032年

Granulocyte-Colony Stimulating Factor Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

顆粒細胞增生因子(G-CSF) 市場預計到 2032 年將成長至 70.5 億美元，複合年成長率為 9.69%。

主要市場統計數據
基準年 2025 36.9億美元
預計年份：2026年 39.6億美元
預測年份 2032 70.5億美元
複合年成長率 (%) 9.69%

顆粒細胞增生因子：概述

顆粒細胞增生因子(G-CSF) 是一種嗜中性白血球低下症化療相關的中性粒細胞減少症、促進幹細胞募集以及治療某些嚴重的慢性嗜中性白血球低下症。治療方案包括短效和長效製劑，治療方案的選擇取決於化療方案、感染風險、患者特徵、醫療機構以及當地臨床指南。生物相似藥的可近性、給藥便利性和醫保報銷政策是影響藥物可近性和處方決策的重要因素。

臨床標準化和生物相似藥的競爭正在改變我們的行醫方式。

醫療保健格局正朝著基於方案的預防嗜中性白血球低下症減少症、更廣泛地應用基於風險的支持性治療以及更加重視門診給藥的方向轉變。生物相似藥在加劇現有生物製藥的競爭壓力的同時，也需要持續關注互換性法規、藥物安全監測、臨床醫師的信心以及醫病溝通。長效製劑和給藥方法可以減輕注射負擔，但其應用取決於實證醫學證據、成本效益、物流以及與化療方案的兼容性。

透過人工智慧 (AI) 提高風險分層和營運效率

人工智慧 (AI) 可嗜中性白血球低下症。預測工具還可以改善給藥計畫、給藥​​時間安排、不利事件監測，並識別需要增加劑量或進行追蹤的患者。由於治療決策仍然依賴臨床判斷和已批准的適應症，因此這些應用需要具有代表性的臨床數據、透明的檢驗、人工監督以及防止偏差的安全機制。

區域性見解：存取、指南和交付模式各不相同。

在北美，除了成熟的腫瘤醫療基礎設施外，還強調指南遵循、支付方管控和生物相似藥的推廣應用。在歐洲，醫療技術評估、國家報銷決策和協調一致的監管標準備受重視，但各國之間的差異會影響生物相似藥的推廣應用。亞太地區既有擁有完善支持性治療路徑的已開發市場，也有快速擴張的醫療體系，但可負擔性和分配仍是該地區面臨的主要挑戰。拉丁美洲的特點是公共部門採購、醫療服務取得不均以及公私合作模式的差異。在中東，腫瘤專科醫療體系的投資正在推進，但醫療服務的可近性取決於各國醫療體系的資源狀況。非洲在診斷、癌症治療的可近性、冷鏈的可靠性和支持性治療的連續性方面都存在顯著差異。

群體特定見解：經濟和政策集團對實施的影響

在東協市場，由於各市場監管成熟度和購買力存在差異，區域協調和供應可靠性至關重要。金磚國家成員國的癌症治療體系涵蓋從先進到發展中的各個階段，國內生產、公共採購和可負擔性等因素都會影響治療的可近性。歐盟受益於通用的監管原則，但在報銷和臨床實施方面仍存在國別差異。七國集團（G7）國家普遍擁有完善的腫瘤治療基礎設施，但控制成本和確保公平取得仍然是優先事項。海灣合作理事會（GCC）國家正在擴展其專科醫療體系，並可能採用集中採購和國際臨床標準。北約成員國的醫療保健體系各不相同，因此加入北約並不一定意味著能夠平等地獲得治療或政策支持。

國家層面洞察：國家醫療保健系統決定臨床覆蓋範圍

澳洲和加拿大在其地域分散的醫療保健系統中強調循證報銷。巴西和墨西哥面臨著醫療服務可近性方面的區域差異，公共採購在其中發揮著至關重要的作用。中國正在加強其癌症醫療體系，同時兼顧可負擔性、監管發展和國內供應目標。法國、德國、義大利、西班牙和英國擁有系統性的臨床和報銷框架，但在評估、競標和交付管道方面存在差異。印度擁有大型專科醫療中心，但醫療服務的可近性因邦和收入水平而異。日本和韓國擁有先進的臨床基礎設施，並滿足老齡化社會的需求，此外還制定了詳細的報銷和監管要求。俄羅斯的醫療服務可近性受國內生產、採購政策和醫療保健系統狀況的影響。在美國，治療選擇範圍廣泛，但支付方、執業地點和經濟承受能力有顯著差異。

優先考慮實證醫學、韌性和以病人為中心的醫療服務。

產業領導者必須將產品開發和商業化與明確定義的嗜中性白血球低下症風險群、比較證據和真實世界臨床結果相結合。為增強人們對生物相似藥的信心，透明的分析和臨床證據、可靠的藥物安全監測以及對處方醫生和患者的教育至關重要。供應策略應實現生產和冷鏈路線的多元化，市場准入計畫應涵蓋公共採購、報銷證據和區域差異等議題。數位化和人工智慧工具的實施應遵循檢驗的工作流程、網路安全措施和臨床醫生的監督。病患支援應著重於藥物依從性、注射指導、感染疾病徵兆的識別以及癌症專科中心與社區醫療機構之間的協作。

調查方法：基於證據的臨床和市場促進因素綜合分析。

本執行摘要基於G-CSF市場的既定範圍，從臨床應用、製劑趨勢、生物相似藥趨勢、政策、可近性和醫療服務等方面對研究結果進行了梳理。這些見解來自既定的臨床實踐理念、監管和報銷考慮、同行評審的證據以及公開記錄的醫療系統特徵。區域、群體和國家間的比較均為定性分析，並不代表市場規模估算、預測、佔有率或排名。隨著指南、核准、採購規則和安全性證據的變化，相關解讀也應及時更新。

結論：獲得粒細胞集落刺激因子取決於價值觀、信任和執行力。

粒細胞集落刺激因子（G-CSF）仍然是腫瘤和某些血液系統疾病的重要支持療法。未來的進展並非取決於單一產品特性，而是取決於臨床證據、對生物相似藥的信任、可負擔性、供應穩定性、給藥便利性以及數據和人工智慧的合理應用等因素的綜合作用。將創新與基於指南的醫療實踐和可衡量的患者療效相結合的機構，將更有能力改善不同醫療保健系統中的藥物可近性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：顆粒細胞增生因子市場：依產品類型分類

  • 生物相似藥
    • Filgrastim生物相似藥
    • Pegfilgrastim生物相似藥
  • 原廠產品
    • Filgrastim
    • 來諾格拉司亭
    • Pegfilgrastim

第8章：顆粒細胞增生因子市場：依給藥途徑分類

  • 靜脈
  • 皮下

第9章：顆粒細胞增生因子市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章：顆粒細胞增生因子市場：依應用領域分類

  • 預防化療引起的嗜中性白血球低下症
  • 嚴重慢性嗜中性白血球低下症的治療
  • 幹細胞動員

第11章：顆粒細胞增生因子市場：依最終用戶分類

  • 居家照護環境
  • 醫院
  • 腫瘤診所

第12章：顆粒細胞增生因子市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章：顆粒細胞增生因子市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：顆粒細胞增生因子市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Amgen Inc.
  • BIOCAD
  • Biocon
  • Celltrion, Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Kyowa Kirin Co., Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sandoz International GmbH
  • Spectrum Pharmaceuticals, Inc.
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

第17章 主要專家

Product Code: MRR-961F26FD6426

The Granulocyte-Colony Stimulating Factor Market is projected to grow by USD 7.05 billion at a CAGR of 9.69% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.69 billion
Estimated Year [2026] USD 3.96 billion
Forecast Year [2032] USD 7.05 billion
CAGR (%) 9.69%

Granulocyte-Colony Stimulating Factor: Executive Overview

Granulocyte-colony stimulating factor (G-CSF) is a hematopoietic growth factor used primarily to reduce or manage chemotherapy-associated neutropenia, support stem-cell mobilization, and treat selected severe chronic neutropenia conditions. The therapeutic landscape includes short-acting and long-acting approaches, with treatment selection shaped by chemotherapy regimen, infection risk, patient characteristics, care setting, and local clinical guidance. Biosimilar availability, administration convenience, and reimbursement policy are important factors influencing access and prescribing decisions.

Clinical Standardization and Biosimilar Competition Are Reshaping Care

The landscape is shifting toward more protocol-driven prevention of febrile neutropenia, wider use of risk-adapted supportive care, and greater emphasis on outpatient administration. Biosimilars are increasing competitive pressure around established biologic therapies while requiring continued attention to interchangeability rules, pharmacovigilance, clinician confidence, and patient communication. Longer-acting formulations and delivery options can reduce injection burden, but adoption depends on evidence, affordability, logistics, and alignment with chemotherapy schedules.

Artificial Intelligence Is Strengthening Risk Stratification and Operations

Artificial intelligence can support G-CSF utilization by identifying patients at elevated risk of neutropenia, integrating laboratory trends with treatment histories, and helping care teams prioritize monitoring. Predictive tools may also improve scheduling, dose-timing workflows, adverse-event surveillance, and identification of patients who need escalation or follow-up. These applications require representative clinical data, transparent validation, human oversight, and safeguards against bias, because treatment decisions remain dependent on clinical judgment and approved indications.

Regional Insights: Access, Guidelines, and Delivery Models Differ

North America combines mature oncology infrastructure with strong attention to guideline adherence, payer controls, and biosimilar adoption. Europe emphasizes health-technology assessment, national reimbursement decisions, and coordinated regulatory standards, while variation among countries affects uptake. Asia-Pacific includes advanced markets with established supportive-care pathways alongside rapidly expanding systems where affordability and distribution remain central. Latin America is shaped by public-sector procurement, uneven access, and private-public differences. The Middle East is investing in specialized oncology capacity, with access varying by national health-system resources. Africa faces substantial disparities in diagnosis, cancer treatment availability, cold-chain reliability, and continuity of supportive care.

Group Insights: Economic and Policy Blocs Shape Adoption

ASEAN markets show varied regulatory maturity and purchasing capacity, making regional harmonization and supply reliability important. BRICS members span advanced and developing oncology systems, with domestic manufacturing, public procurement, and affordability influencing access. The European Union benefits from shared regulatory principles but retains national differences in reimbursement and clinical implementation. G7 countries generally have robust oncology infrastructure, although cost containment and equitable access remain priorities. GCC systems are expanding specialist capacity and may adopt centralized procurement and international clinical standards. NATO members show broad healthcare diversity, so alliance membership does not translate into uniform treatment access or policy.

Country Insights: National Systems Determine Clinical Reach

Australia and Canada emphasize evidence-based reimbursement within geographically dispersed systems. Brazil and Mexico face regional access differences and a meaningful role for public procurement. China is strengthening oncology capacity while balancing affordability, regulatory development, and domestic supply objectives. France, Germany, Italy, Spain, and the United Kingdom apply structured clinical and reimbursement frameworks, with differences in assessment, tendering, and delivery pathways. India combines major specialist centers with uneven access across states and income groups. Japan and South Korea have advanced clinical infrastructure and aging-population needs, alongside detailed reimbursement and regulatory requirements. Russia's access is influenced by domestic production, procurement policy, and healthcare-system conditions. The United States has broad treatment availability but significant payer, site-of-care, and affordability variation.

Prioritize Evidence, Resilience, and Patient-Centered Delivery

Industry leaders should align product development and commercialization with clearly defined neutropenia-risk populations, comparative evidence, and real-world outcomes. Strengthening biosimilar confidence requires transparent analytical and clinical evidence, reliable pharmacovigilance, and education for prescribers and patients. Supply strategies should diversify manufacturing and cold-chain pathways, while market access plans should address public procurement, reimbursement evidence, and regional inequities. Digital and AI-enabled tools should be deployed with validated workflows, cybersecurity controls, and clinician oversight. Patient support should focus on adherence, injection education, infection-warning awareness, and coordination between oncology centers and community care.

Methodology: Evidence-Based Synthesis of Clinical and Market-Access Drivers

This executive summary uses the defined G-CSF market scope and organizes findings across clinical use, formulation trends, biosimilar dynamics, policy, access, and healthcare delivery. Insights are derived from established clinical practice concepts, regulatory and reimbursement considerations, peer-reviewed evidence, and publicly documented healthcare-system characteristics. Regional, group, and country comparisons are qualitative; they do not represent market estimates, forecasts, shares, or rankings. Interpretation should be updated as guidelines, approvals, procurement rules, and safety evidence evolve.

Conclusion: G-CSF Access Will Depend on Value, Trust, and Execution

G-CSF remains an important supportive-care intervention in oncology and selected hematologic conditions. Future progress will be determined less by a single product attribute than by the combined effect of clinical evidence, biosimilar confidence, affordability, supply resilience, delivery convenience, and responsible use of data and AI. Organizations that connect innovation with guideline-based care and measurable patient outcomes will be better positioned to improve access across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Granulocyte-Colony Stimulating Factor Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biosimilar
    • 7.2.1. Filgrastim Biosimilar
    • 7.2.2. Pegfilgrastim Biosimilar
  • 7.3. Originator
    • 7.3.1. Filgrastim
    • 7.3.2. Lenograstim
    • 7.3.3. Pegfilgrastim

8. Granulocyte-Colony Stimulating Factor Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Subcutaneous

9. Granulocyte-Colony Stimulating Factor Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Pharmacy
  • 9.4. Retail Pharmacy

10. Granulocyte-Colony Stimulating Factor Market, by Application

  • 10.1. Introduction
  • 10.2. Chemotherapy Induced Neutropenia Prophylaxis
  • 10.3. Severe Chronic Neutropenia Treatment
  • 10.4. Stem Cell Mobilization

11. Granulocyte-Colony Stimulating Factor Market, by End User

  • 11.1. Introduction
  • 11.2. Homecare Settings
  • 11.3. Hospitals
  • 11.4. Oncology Clinics

12. Granulocyte-Colony Stimulating Factor Market, by Region

  • 12.1. Introduction
  • 12.2. Asia-Pacific
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Europe
  • 12.6. Middle East
  • 12.7. Africa

13. Granulocyte-Colony Stimulating Factor Market, by Group

  • 13.1. Introduction
  • 13.2. ASEAN
  • 13.3. GCC
  • 13.4. European Union
  • 13.5. BRICS
  • 13.6. G7
  • 13.7. NATO

14. Granulocyte-Colony Stimulating Factor Market, by Country

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. United Kingdom
  • 14.7. Germany
  • 14.8. France
  • 14.9. Russia
  • 14.10. Italy
  • 14.11. Spain
  • 14.12. China
  • 14.13. India
  • 14.14. Japan
  • 14.15. Australia
  • 14.16. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. Market Concentration Analysis, 2025
    • 15.2.1. Concentration Ratio (CR)
    • 15.2.2. Herfindahl Hirschman Index (HHI)
  • 15.3. Recent Developments & Impact Analysis, 2025
  • 15.4. Product Portfolio Analysis, 2025
  • 15.5. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Amgen Inc.
  • 16.2. BIOCAD
  • 16.3. Biocon
  • 16.4. Celltrion, Inc.
  • 16.5. Coherus BioSciences, Inc.
  • 16.6. Dr. Reddy's Laboratories Ltd.
  • 16.7. GlaxoSmithKline plc
  • 16.8. Intas Pharmaceuticals Ltd.
  • 16.9. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 16.10. Kyowa Kirin Co., Ltd.
  • 16.11. Merck KGaA
  • 16.12. Novartis AG
  • 16.13. Pfizer Inc.
  • 16.14. Sandoz International GmbH
  • 16.15. Spectrum Pharmaceuticals, Inc.
  • 16.16. STADA Arzneimittel AG
  • 16.17. Teva Pharmaceutical Industries Ltd.
  • 16.18. Viatris Inc.

17. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global Granulocyte-Colony Stimulating Factor Market, Years Considered for the Study
  • FIGURE 2. Global Granulocyte-Colony Stimulating Factor Market, Research Design
  • FIGURE 3. Global Granulocyte-Colony Stimulating Factor Market, Research Framework
  • FIGURE 4. Global Granulocyte-Colony Stimulating Factor Market, Data Triangulation
  • FIGURE 5. Global Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2025 vs 2032 (%)
  • FIGURE 7. Global Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 11. Global Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global Granulocyte-Colony Stimulating Factor Market Size, by Application, 2025 vs 2032 (%)
  • FIGURE 13. Global Granulocyte-Colony Stimulating Factor Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global Granulocyte-Colony Stimulating Factor Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 15. Global Granulocyte-Colony Stimulating Factor Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global Granulocyte-Colony Stimulating Factor Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 17. Global Granulocyte-Colony Stimulating Factor Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global Granulocyte-Colony Stimulating Factor Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global Granulocyte-Colony Stimulating Factor Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 20. Global Granulocyte-Colony Stimulating Factor Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global Granulocyte-Colony Stimulating Factor Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global Granulocyte-Colony Stimulating Factor Market Segmentation & Coverage
  • TABLE 2. Global Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 4. Global Biosimilar Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Biosimilar Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Biosimilar Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Filgrastim Biosimilar Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Filgrastim Biosimilar Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Filgrastim Biosimilar Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Pegfilgrastim Biosimilar Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Pegfilgrastim Biosimilar Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Pegfilgrastim Biosimilar Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Originator Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Originator Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Originator Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Filgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Filgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Filgrastim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Lenograstim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Lenograstim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Lenograstim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Pegfilgrastim Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Pegfilgrastim Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Pegfilgrastim Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 26. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 27. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 28. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 29. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 30. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 31. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 32. Global Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 33. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 34. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 35. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 36. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 37. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 38. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 39. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 40. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 41. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 42. Global Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 43. Global Chemotherapy Induced Neutropenia Prophylaxis Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Chemotherapy Induced Neutropenia Prophylaxis Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Chemotherapy Induced Neutropenia Prophylaxis Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Severe Chronic Neutropenia Treatment Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Severe Chronic Neutropenia Treatment Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Severe Chronic Neutropenia Treatment Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global Stem Cell Mobilization Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 50. Global Stem Cell Mobilization Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 51. Global Stem Cell Mobilization Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 52. Global Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 53. Global Homecare Settings Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Homecare Settings Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Homecare Settings Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Oncology Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Oncology Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Oncology Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Granulocyte-Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 64. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 65. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 66. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 67. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 68. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 69. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 70. Asia-Pacific Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 71. North America Granulocyte-Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 72. North America Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 73. North America Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 74. North America Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 75. North America Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 76. North America Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 77. North America Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 78. North America Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 79. Latin America Granulocyte-Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Latin America Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 81. Latin America Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 82. Latin America Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 83. Latin America Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 84. Latin America Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 85. Latin America Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 86. Latin America Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 87. Europe Granulocyte-Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 88. Europe Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 89. Europe Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 90. Europe Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 91. Europe Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 92. Europe Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 93. Europe Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 94. Europe Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 95. Middle East Granulocyte-Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 96. Middle East Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 97. Middle East Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 98. Middle East Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 99. Middle East Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 100. Middle East Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 101. Middle East Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 102. Middle East Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 103. Africa Granulocyte-Colony Stimulating Factor Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 104. Africa Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 105. Africa Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 106. Africa Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 107. Africa Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 108. Africa Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 109. Africa Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 110. Africa Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 111. Global Granulocyte-Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 113. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 114. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 115. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 116. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 117. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 118. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 119. ASEAN Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 120. GCC Granulocyte-Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 121. GCC Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 122. GCC Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 123. GCC Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 124. GCC Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 125. GCC Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 126. GCC Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 127. GCC Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 128. European Union Granulocyte-Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 129. European Union Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 130. European Union Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 131. European Union Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 132. European Union Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 133. European Union Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 134. European Union Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 135. European Union Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 136. BRICS Granulocyte-Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. BRICS Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 138. BRICS Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 139. BRICS Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 140. BRICS Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 141. BRICS Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 142. BRICS Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 143. BRICS Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 144. G7 Granulocyte-Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 145. G7 Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 146. G7 Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 147. G7 Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 148. G7 Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 149. G7 Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 150. G7 Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 151. G7 Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 152. NATO Granulocyte-Colony Stimulating Factor Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 153. NATO Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 154. NATO Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 155. NATO Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 156. NATO Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 157. NATO Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 158. NATO Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 159. NATO Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 160. Global Granulocyte-Colony Stimulating Factor Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 161. United States Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 162. United States Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 163. United States Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 164. United States Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 165. United States Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 166. United States Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 167. United States Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 168. United States Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 169. Canada Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 170. Canada Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 171. Canada Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 172. Canada Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 173. Canada Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 174. Canada Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 175. Canada Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 176. Canada Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 177. Mexico Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 178. Mexico Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 179. Mexico Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 180. Mexico Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 181. Mexico Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 182. Mexico Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 183. Mexico Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 184. Mexico Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 185. Brazil Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 186. Brazil Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 187. Brazil Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 188. Brazil Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 189. Brazil Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 190. Brazil Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 191. Brazil Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 192. Brazil Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 194. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 195. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 196. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 197. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 198. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 199. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 200. United Kingdom Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 201. Germany Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 202. Germany Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 203. Germany Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 204. Germany Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 205. Germany Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 206. Germany Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 207. Germany Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 208. Germany Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 209. France Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 210. France Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 211. France Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 212. France Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 213. France Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 214. France Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 215. France Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 216. France Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 217. Russia Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 218. Russia Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 219. Russia Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 220. Russia Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 221. Russia Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 222. Russia Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 223. Russia Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 224. Russia Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 225. Italy Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 226. Italy Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 227. Italy Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 228. Italy Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 229. Italy Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 230. Italy Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 231. Italy Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 232. Italy Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 233. Spain Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 234. Spain Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 235. Spain Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 236. Spain Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 237. Spain Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 238. Spain Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 239. Spain Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 240. Spain Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 241. China Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 242. China Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 243. China Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 244. China Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 245. China Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 246. China Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 247. China Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 248. China Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 249. India Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 250. India Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 251. India Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 252. India Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 253. India Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 254. India Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 255. India Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 256. India Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 257. Japan Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 258. Japan Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 259. Japan Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 260. Japan Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 261. Japan Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 262. Japan Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 263. Japan Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 264. Japan Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 265. Australia Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 266. Australia Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 267. Australia Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 268. Australia Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 269. Australia Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 270. Australia Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 271. Australia Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 272. Australia Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 273. South Korea Granulocyte-Colony Stimulating Factor Market Size, 2017-2032 (USD Million)
  • TABLE 274. South Korea Granulocyte-Colony Stimulating Factor Market Size, by Product Type, 2017-2032 (USD Million)
  • TABLE 275. South Korea Granulocyte-Colony Stimulating Factor Market Size, by Biosimilar, 2017-2032 (USD Million)
  • TABLE 276. South Korea Granulocyte-Colony Stimulating Factor Market Size, by Originator, 2017-2032 (USD Million)
  • TABLE 277. South Korea Granulocyte-Colony Stimulating Factor Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 278. South Korea Granulocyte-Colony Stimulating Factor Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 279. South Korea Granulocyte-Colony Stimulating Factor Market Size, by Application, 2017-2032 (USD Million)
  • TABLE 280. South Korea Granulocyte-Colony Stimulating Factor Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 281. Global Granulocyte-Colony Stimulating Factor Market Share, by Key Player, 2025
  • TABLE 282. Global Granulocyte-Colony Stimulating Factor Market, Key Experts